• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名肺动脉高压患者在开始使用枸橼酸西地那非后发生视网膜中央静脉阻塞。

Central retinal vein occlusion in a patient after being commenced on sildenafil citrate for pulmonary arterial hypertension.

作者信息

Pinto Lancelot M, Morekar Sunil, Mahashur Ashok A

机构信息

Department of Pulmonology, P D Hinduja National Hospital and Medical Research Centre, Mumbai (Maharashtra), India.

出版信息

Indian J Chest Dis Allied Sci. 2009 Oct-Dec;51(4):249-51.

PMID:20073379
Abstract

A 75-year-old female was commenced on sildenafil for the treatment of pulmonary arterial hypertension (PAH) secondary to chronic obstructive pulmonary disease (COPD). She reported blurring of vision within 72 hours after starting treatment and was found to have a central retinal vein occlusion (CRVO). Such an occurrence is the second case reported to date, and we review the possible mechanisms and literature on the subject.

摘要

一名75岁女性开始使用西地那非治疗慢性阻塞性肺疾病(COPD)继发的肺动脉高压(PAH)。她在开始治疗后72小时内报告视力模糊,经检查发现患有视网膜中央静脉阻塞(CRVO)。这种情况是迄今为止报告的第二例,我们回顾了该主题的可能机制及相关文献。

相似文献

1
Central retinal vein occlusion in a patient after being commenced on sildenafil citrate for pulmonary arterial hypertension.一名肺动脉高压患者在开始使用枸橼酸西地那非后发生视网膜中央静脉阻塞。
Indian J Chest Dis Allied Sci. 2009 Oct-Dec;51(4):249-51.
2
Sildenafil citrate therapy for pulmonary arterial hypertension.枸橼酸西地那非治疗肺动脉高压
N Engl J Med. 2006 Mar 9;354(10):1091-3; author reply 1091-3.
3
Optic atrophy after sildenafil use.使用西地那非后出现视神经萎缩。
Optometry. 2007 Jul;78(7):329; author reply 329-30. doi: 10.1016/j.optm.2007.05.005.
4
Sildenafil citrate therapy for pulmonary arterial hypertension.枸橼酸西地那非治疗肺动脉高压
N Engl J Med. 2006 Mar 9;354(10):1091-3; author reply 1091-3.
5
[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].[肺动脉高压的治疗:磷酸二酯酶-5抑制剂]
Dtsch Med Wochenschr. 2006 Dec 8;131(49 Suppl 9):S311-4. doi: 10.1055/s-2006-957199.
6
Sildenafil in pulmonary hypertension.西地那非治疗肺动脉高压
Indian Heart J. 2003 May-Jun;55(3):285; author reply 285.
7
Sildenafil citrate therapy for pulmonary arterial hypertension.枸橼酸西地那非治疗肺动脉高压
N Engl J Med. 2005 Nov 17;353(20):2148-57. doi: 10.1056/NEJMoa050010.
8
Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.用于治疗肺动脉高压的5型磷酸二酯酶抑制剂。
N Engl J Med. 2009 Nov 5;361(19):1864-71. doi: 10.1056/NEJMct0904473.
9
Optic atrophy after sildenafil use.使用西地那非后出现视神经萎缩。
Optometry. 2007 Mar;78(3):122-8. doi: 10.1016/j.optm.2007.01.005.
10
Sildenafil in primary pulmonary hypertension.西地那非治疗原发性肺动脉高压
N Engl J Med. 2000 Nov 2;343(18):1342. doi: 10.1056/NEJM200011023431814.

引用本文的文献

1
Central retinal vein and artery occlusion associated with sildenafil: a case report and review of the literature.与西地那非相关的视网膜中央静脉和动脉阻塞:病例报告及文献复习。
J Med Case Rep. 2023 Sep 20;17(1):399. doi: 10.1186/s13256-023-04104-8.
2
Case report: Bilateral central serous chorioretinopathy-like abnormalities in a man with pulmonary arterial hypertension.病例报告:一名患有肺动脉高压的男性出现双侧中心性浆液性脉络膜视网膜病变样异常。
Front Med (Lausanne). 2022 Aug 1;9:983548. doi: 10.3389/fmed.2022.983548. eCollection 2022.
3
Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US.
美国男性使用磷酸二酯酶 5 抑制剂与眼部不良事件风险相关。
JAMA Ophthalmol. 2022 May 1;140(5):480-484. doi: 10.1001/jamaophthalmol.2022.0663.
4
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.5型磷酸二酯酶抑制剂与视觉副作用:一篇叙述性综述。
J Ophthalmic Vis Res. 2021 Apr 29;16(2):248-259. doi: 10.18502/jovr.v16i2.9088. eCollection 2021 Apr-Jun.
5
[Acute monocular loss of vision : Differential diagnostic considerations apart from the internistic etiological clarification].[急性单眼视力丧失:除内科病因明确外的鉴别诊断考量]
Ophthalmologe. 2018 Aug;115(8):676-679. doi: 10.1007/s00347-017-0555-2.